[go: up one dir, main page]

DK1223980T3 - Anvendelse af CSF-1-inhibitorer - Google Patents

Anvendelse af CSF-1-inhibitorer

Info

Publication number
DK1223980T3
DK1223980T3 DK00972422T DK00972422T DK1223980T3 DK 1223980 T3 DK1223980 T3 DK 1223980T3 DK 00972422 T DK00972422 T DK 00972422T DK 00972422 T DK00972422 T DK 00972422T DK 1223980 T3 DK1223980 T3 DK 1223980T3
Authority
DK
Denmark
Prior art keywords
csf
inhibitors
medicament
preparing
activity
Prior art date
Application number
DK00972422T
Other languages
English (en)
Inventor
Seyedhossein Aharinejad
Original Assignee
Seyedhossein Aharinejad
Hofbauer Reinhold
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3521549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1223980(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seyedhossein Aharinejad, Hofbauer Reinhold filed Critical Seyedhossein Aharinejad
Application granted granted Critical
Publication of DK1223980T3 publication Critical patent/DK1223980T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/111Antisense spanning the whole gene, or a large part of it
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK00972422T 1999-10-28 2000-10-25 Anvendelse af CSF-1-inhibitorer DK1223980T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT181399 1999-10-28
PCT/AT2000/000281 WO2001030381A2 (de) 1999-10-28 2000-10-25 Verwendung von csf-1-inhibitoren

Publications (1)

Publication Number Publication Date
DK1223980T3 true DK1223980T3 (da) 2003-09-15

Family

ID=3521549

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00972422T DK1223980T3 (da) 1999-10-28 2000-10-25 Anvendelse af CSF-1-inhibitorer

Country Status (11)

Country Link
US (1) US20090317403A1 (da)
EP (1) EP1223980B1 (da)
JP (2) JP4307775B2 (da)
AT (1) ATE240744T1 (da)
AU (1) AU783063B2 (da)
CA (1) CA2388298C (da)
DE (1) DE50002293D1 (da)
DK (1) DK1223980T3 (da)
ES (1) ES2197885T3 (da)
PT (1) PT1223980E (da)
WO (1) WO2001030381A2 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1223980B1 (de) * 1999-10-28 2003-05-21 Hofbauer, Reinhold Verwendung von csf-1-inhibitoren
US7247618B2 (en) 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
JP2005525314A (ja) * 2002-01-03 2005-08-25 トランジェーヌ、ソシエテ、アノニム 抗腫瘍療法のために使用可能な組み合わせ物
ES2345885T3 (es) 2002-11-15 2010-10-05 Novartis Vaccines And Diagnostics, Inc. Metodos para prevenir y tratar metastasis de cancer y perdida de hueso asociada con la metastasis de cancer.
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
BRPI0506726B8 (pt) * 2004-01-07 2021-05-25 Chiron Corp anticorpo monoclonal específico para m-csf e usos deste
US8652469B2 (en) 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
WO2009026303A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Human c-fms antigen binding proteins
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
NZ587830A (en) 2008-03-14 2012-08-31 Transgene Sa Antibody against the colony-stimulating factor-1 receptor (CSF-1R)
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
WO2010062399A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Csf1r extracellular domain fusion molecules and treatments using same
GB0910833D0 (en) * 2009-06-23 2009-08-05 Univ Edinburgh Avian genes
CN105218672A (zh) 2009-12-10 2016-01-06 霍夫曼-拉罗奇有限公司 优先结合人csf1r胞外域4的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
CN112480256A (zh) 2010-05-04 2021-03-12 戊瑞治疗有限公司 结合csf1r的抗体
ES2618828T3 (es) 2011-07-18 2017-06-22 The University Of Melbourne Uso de antagonistas de c-Fms
CA2853889A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
BR112015004426A2 (pt) 2012-08-31 2018-08-28 Five Prime Therapeutics, Inc. método para reduzir o nível, tratar uma condição, tratar uma condição inflamatória, tratar distúrbio de cd16+, tratar um respondente inadequado de metotrexate, tratar um respondente inadequado de inibidor de tnf, indentificar um sujeito, predizer responsividade e métodos para tratar uma condição inflamatória
MX2015014198A (es) 2013-04-12 2015-12-11 Morphosys Ag Anticuerpos cuyo objetivo es m-csf.
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
BR112016029460A2 (pt) 2014-06-23 2017-10-24 Five Prime Therapeutics Inc métodos para tratar artrite reumatoide
IL251464B2 (en) 2014-10-29 2023-03-01 Five Prime Therapeutics Inc Combination therapy for cancer
BR112017013111A2 (pt) 2014-12-22 2018-05-15 Five Prime Therapeutics Inc métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
JP6971850B2 (ja) 2015-04-13 2021-11-24 ファイヴ プライム セラピューティクス インク がんの併用療法
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
MY195000A (en) * 2015-05-27 2022-12-30 Ucb Biopharma Sprl Method for the treatment of neurological disease
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
CN121159691A (zh) 2017-05-12 2025-12-19 哈普恩治疗公司 间皮素结合蛋白质
KR20240042244A (ko) 2017-05-19 2024-04-01 신닥스 파마슈티컬스, 인크. 조합 요법
CA3073531A1 (en) 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
EA202090817A1 (ru) 2017-10-13 2020-09-08 Харпун Терапьютикс, Инк. Триспецифические белки и способы их применения
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性rna
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるcd40およびcd137に対する多重特異性結合剤
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4504586A (en) * 1983-02-03 1985-03-12 Amgen Hybridoma tumor cell lines and their monoclonal antibodies to human colony stimulating factor subclass number 1
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
CA2132091C (en) * 1992-04-03 2008-09-16 Kyung J. Kim Antibodies to alphavbeta3 integrin
WO1999032148A1 (en) * 1997-12-19 1999-07-01 Beth Israel Deaconess Medical Center Methods and compositions for inhibiting tumor cell growth
EP1223980B1 (de) * 1999-10-28 2003-05-21 Hofbauer, Reinhold Verwendung von csf-1-inhibitoren

Also Published As

Publication number Publication date
EP1223980A2 (de) 2002-07-24
EP1223980B1 (de) 2003-05-21
JP4307775B2 (ja) 2009-08-05
WO2001030381A3 (de) 2001-12-06
AU783063B2 (en) 2005-09-22
DE50002293D1 (de) 2003-06-26
CA2388298A1 (en) 2001-05-03
JP2003525870A (ja) 2003-09-02
AU1114501A (en) 2001-05-08
CA2388298C (en) 2013-05-14
ES2197885T3 (es) 2004-01-16
ATE240744T1 (de) 2003-06-15
PT1223980E (pt) 2003-10-31
US20090317403A1 (en) 2009-12-24
WO2001030381A2 (de) 2001-05-03
JP2009143930A (ja) 2009-07-02

Similar Documents

Publication Publication Date Title
DK1223980T3 (da) Anvendelse af CSF-1-inhibitorer
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
AU7031500A (en) Therapeutic quinazoline compounds
CY2013020I1 (el) Η χρηση μιας ενωσης ινγκενανης για την κατασκευη ενος φαρμακου για την θεραπεια του καρκινου
DE50310516D1 (de) Fredericamycin-derivate
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
DE60223254D1 (de) Verzögert freisetzende formulierungen von oxymorphon
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
IT1319202B1 (it) Farmaci per le malattie a base infiammatoria.
DE60100625D1 (de) Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina
CY1106122T1 (el) Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση της νοσου ευepεθιστου εντερου
DE50201780D1 (de) Halogensubstituierte aminodicarbonsäurederivate als arzneimittel zur behandlung von herz-kreislauf-erkrankungen
ATE296827T1 (de) Heteropolycyclische inhibitoren
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
IT1318667B1 (it) Medicamento antinfiammatorio.
GB9907571D0 (en) Compounds
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
SE0004827D0 (sv) Therapeutic compounds
ITRM990719A0 (it) Uso di ubichinone q10 per il trattamento locale e la prevenzione di patalogie aftalmologiche secondarie alla terapia fotorefrattiva, chirurg
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων